<DOC>
	<DOCNO>NCT00241462</DOCNO>
	<brief_summary>The purpose study identify patient , receive Faslodex within approve label , benefit Faslodex treatment .</brief_summary>
	<brief_title>Faslodex Observations During Regular Use Advanced Mammacarcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Postmenopausal Locally advance metastatic hormone sensitive breast cancer know estrogen receptor ( ER ) progesterone receptor ( PR ) status Patient recurrence adjuvant antioestrogen treatment progression disease antioestrogen treatment Life threatening metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
</DOC>